Ben Broster has joined fellow prop Cobus Visagie in signing a new Saracens contract. Just days after securing the future of Cobus Visagie, Saracens have tied prop Ben Broster to a new two-year deal.

Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68. Corbus ...

Corbus Pharmaceuticals has a 52 week low of $9.11 and a 52 week high of $61.90. The stock has a market cap of $119.11 million, a P/E ratio of -2.09 and a beta of 2.63. Institutional Inflows and ...

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an ...

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...